Literature DB >> 20694120

The effect of antipsychotic medication on neuromotor abnormalities in neuroleptic-naive nonaffective psychotic patients: a naturalistic study with haloperidol, risperidone, or olanzapine.

Victor Peralta1, Manuel J Cuesta.   

Abstract

OBJECTIVE: To examine the effect of antipsychotic medication on neuromotor abnormalities in a sample of psychotic patients never exposed to antipsychotic drugs.
METHOD: One hundred psychotic patients were assessed (from January 1998 to December 2002) using DSM-IV criteria for parkinsonism, dyskinesia, akathisia, catatonia, and dystonia at baseline and after 4 weeks of treatment with haloperidol (n = 23), risperidone (n = 52), or olanzapine (n = 25). We examined change scores in neuromotor ratings over the treatment period across treatment groups and rates of drug-responsive and drug-emergent neuromotor syndromes in patients with and without preexisting neuromotor abnormalities.
RESULTS: Overall time effects revealed a worsening of parkinsonism (P = .002) and akathisia (P = .002) ratings and an improvement of dyskinesia (P = .001) and catatonia (P < .001) ratings. Main treatment effects revealed that patients taking haloperidol had a significant mean increase in akathisia scores compared with those of patients taking risperidone (P = .002) or olanzapine (P < .001). A significantly greater percentage of olanzapine-treated patients experienced remission of preexisting parkinsonism than did the other treatment groups (P = .047). Patients without preexisting motor abnormalities were more likely to experience drug-emergent parkinsonism if they were treated with haloperidol or risperidone than with olanzapine (P = .001) and were more likely to experience drug-emergent dystonia (P = .014) and akathisia (P = .013) if they were treated with haloperidol than with risperidone or olanzapine.
CONCLUSIONS: The relationship between antipsychotic medication and neurologic abnormalities is more complex than previously acknowledged since antipsychotic drugs may both improve preexisting abnormalities and cause "de novo" neurologic syndromes. Overall, olanzapine has a more favorable neuromotor profile than risperidone, which in turn has a more favorable profile than haloperidol.

Entities:  

Year:  2010        PMID: 20694120      PMCID: PMC2911000          DOI: 10.4088/PCC.09m00799gry

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


  42 in total

1.  Extrapyramidal side-effects of antipsychotics in a randomised trial.

Authors:  Del D Miller; Stanley N Caroff; Sonia M Davis; Robert A Rosenheck; Joseph P McEvoy; Bruce L Saltz; Silvana Riggio; Miranda H Chakos; Marvin S Swartz; Richard S E Keefe; T Scott Stroup; Jeffrey A Lieberman
Journal:  Br J Psychiatry       Date:  2008-10       Impact factor: 9.319

2.  Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study.

Authors:  Diederik E Tenback; Peter N van Harten; Cees J Slooff; Jim van Os
Journal:  Am J Psychiatry       Date:  2006-08       Impact factor: 18.112

3.  An efficacy analysis of olanzapine treatment data in schizophrenia patients with catatonic signs and symptoms.

Authors:  F Martényi; S Metcalfe; B Schausberger; M R Dossenbach
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

4.  Catatonia and other motor syndromes in a chronically hospitalized psychiatric population.

Authors:  G Bush; G Petrides; A Francis
Journal:  Schizophr Res       Date:  1997-10-17       Impact factor: 4.939

5.  Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine.

Authors:  Jeffrey A Lieberman; Michael Phillips; Hongbin Gu; Scott Stroup; Peiyan Zhang; Lan Kong; Zhongfu Ji; Gary Koch; Robert M Hamer
Journal:  Neuropsychopharmacology       Date:  2003-03-26       Impact factor: 7.853

Review 6.  Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses.

Authors:  Gerard W K Hugenholtz; Eibert R Heerdink; Joost J Stolker; Welmoed E E Meijer; Antoine C G Egberts; Willem A Nolen
Journal:  J Clin Psychiatry       Date:  2006-06       Impact factor: 4.384

7.  Are there more than two syndromes in schizophrenia? A critique of the positive-negative dichotomy.

Authors:  V Peralta; J de Leon; M J Cuesta
Journal:  Br J Psychiatry       Date:  1992-09       Impact factor: 9.319

8.  Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.

Authors:  J P McEvoy; G E Hogarty; S Steingard
Journal:  Arch Gen Psychiatry       Date:  1991-08

Review 9.  Neurological signs and involuntary movements in schizophrenia: intrinsic to and informative on systems pathobiology.

Authors:  Peter F Whitty; Olabisi Owoeye; John L Waddington
Journal:  Schizophr Bull       Date:  2008-09-12       Impact factor: 9.306

Review 10.  Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Authors:  Scott W Woods
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

View more
  20 in total

1.  Characterization of spontaneous Parkinsonism in drug-naive patients with nonaffective psychotic disorders.

Authors:  Victor Peralta; Virginia Basterra; Maria S Campos; Elena García de Jalón; Lucía Moreno-Izco; Manuel J Cuesta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-05-28       Impact factor: 5.270

2.  Aberrant Middle Prefrontal-Motor Cortex Connectivity Mediates Motor Inhibitory Biomarker in Schizophrenia.

Authors:  Xiaoming Du; Fow-Sen Choa; Joshua Chiappelli; Krista M Wisner; George Wittenberg; Bhim Adhikari; Heather Bruce; Laura M Rowland; Peter Kochunov; L Elliot Hong
Journal:  Biol Psychiatry       Date:  2018-06-21       Impact factor: 13.382

3.  Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia.

Authors:  Harald Murck; Thomas Laughren; Femke Lamers; Rosalind Picard; Sebastian Walther; Donald Goff; Stephen Sainati
Journal:  Innov Clin Neurosci       Date:  2015 Mar-Apr

Review 4.  Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies.

Authors:  Katharina Stegmayer; Sebastian Walther; Peter van Harten
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

5.  Aberrant Hyperconnectivity in the Motor System at Rest Is Linked to Motor Abnormalities in Schizophrenia Spectrum Disorders.

Authors:  Sebastian Walther; Katharina Stegmayer; Andrea Federspiel; Stephan Bohlhalter; Roland Wiest; Petra V Viher
Journal:  Schizophr Bull       Date:  2017-09-01       Impact factor: 9.306

Review 6.  Motor Abnormalities: From Neurodevelopmental to Neurodegenerative Through "Functional" (Neuro)Psychiatric Disorders.

Authors:  Victor Peralta; Manuel J Cuesta
Journal:  Schizophr Bull       Date:  2017-09-01       Impact factor: 9.306

7.  Spontaneous parkinsonism is associated with cognitive impairment in antipsychotic-naive patients with first-episode psychosis: a 6-month follow-up study.

Authors:  Manuel J Cuesta; Ana M Sánchez-Torres; Elena García de Jalón; Maria S Campos; Berta Ibáñez; Lucía Moreno-Izco; Víctor Peralta
Journal:  Schizophr Bull       Date:  2013-09-26       Impact factor: 9.306

8.  Low physical activity is associated with two hypokinetic motor abnormalities in psychosis.

Authors:  Sebastian Walther; Irena Vladimirova; Danai Alexaki; Lea Schäppi; Kathrine S F Damme; Vijay A Mittal; Stewart A Shankman; Katharina Stegmayer
Journal:  J Psychiatr Res       Date:  2021-11-08       Impact factor: 4.791

9.  Characterization of the deficit syndrome in drug-naive schizophrenia patients: the role of spontaneous movement disorders and neurological soft signs.

Authors:  Victor Peralta; Lucía Moreno-Izco; Ana Sanchez-Torres; Elena García de Jalón; Maria S Campos; Manuel J Cuesta
Journal:  Schizophr Bull       Date:  2012-12-18       Impact factor: 9.306

10.  Aberrant Force Processing in Schizophrenia.

Authors:  Cristina Martinelli; Francesco Rigoli; Sukhwinder S Shergill
Journal:  Schizophr Bull       Date:  2017-03-01       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.